Report on stage III <i>Pig‐a</i> mutation assays using <i>N</i>‐ethyl‐<i>N</i>‐nitrosourea – comparison with other in vivo genotoxicity endpoints
Zoryana Cammerer(Pfizer (United States)), Maik Schuler(Pfizer (United States)), Thomas J. Shutsky(Pfizer (United States)), William C. Gunther(Pfizer (United States)), Maria Engel(Pfizer (United States)), Javed A. Bhalli(National Center for Toxicological Research), Donna Dickinson(Pfizer (United States)), Robert H. Heflich(National Center for Toxicological Research), Stephanie L. Coffing(Pfizer (United States)), Krista L. Dobo(Pfizer (United States)), Joseph G. Shaddock(National Center for Toxicological Research), Mason G. Pearce(National Center for Toxicological Research), Vasily N. Dobrovolsky(National Center for Toxicological Research), Xuefei Cao(National Center for Toxicological Research), Catherine J. Thiffeault(Pfizer (United States)), Ronald D. Fiedler(Pfizer (United States))
Cited by 40
Related Papers
Arylamine-DNA adducts in vitro and in vivo: their role in bacterial mutagenesis and urinary bladder carcinogenesis
|Environmental Health Perspectives|1983|181
The in vivo Pig-a assay: A report of the International Workshop On Genotoxicity Testing (IWGT) Workgroup
|Mutation Research/Genetic Toxicology and Environmental Mutagenesis|2014|156
Genotoxicity of silver nanoparticles evaluated using the Ames test and in vitro micronucleus assay
|Mutation Research/Genetic Toxicology and Environmental Mutagenesis|2011|147
Derivation of point of departure (PoD) estimates in genetic toxicology studies and their potential applications in risk assessment
|Environmental and Molecular Mutagenesis|2014|147
Strategy for genotoxicity testing: Hazard identification and risk assessment in relation to in vitro testing
|Mutation Research/Genetic Toxicology and Environmental Mutagenesis|2006|131